Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20
Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.Aranzazu Fernández-Martínez, Charles M. Perou, Maki Tanioka et al.|Journal of Clinical Oncology|2019Cited by 7
Abstract P5-02-36: Proteogenomic profiling of fresh frozen core biopsies from CALGB 40601Eric J. Jaehnig, Meenakshi Anurag, Beom‐Jun Kim et al.|Cancer Research|2023Cited by 0